RESUMO
OBJECTIVE: A phase II study of Mifepristone (RU486) was conducted in patients with ovarian cancer whose tumors were resistant to cisplatin and paclitaxel, alone or in combination. PATIENTS AND METHODS: Forty-four patients were accrued into this study. All had ovarian cancer that had become resistant to cisplatin and paclitaxel. Patients received Mifepristone 200 mg orally on a daily basis. Patients were followed by tumor size or CA-125 levels when there was no measurable disease. A dose reduction of Mifepristone was to occur in the event of grade 3/4 hematologic, GI, or liver toxicity, creatinine >2.5%, and grade 4 peripheral neuropathy. RESULTS: Thirty-four patients were evaluable for response. Nine (26.5%) of these patients had a response to Mifepristone. Three(9%) patients had a complete response, and six (17.5%), a partial response. The response of one patient in each group was measured by CA-125 levels while the remainder had measurable disease. The response lasted 1 to 4 months in all but one patient. One patient continues to respond after more than 3 years. The major toxic effect was a rash and this was the major reason patients were removed from the study. CONCLUSION: Mifepristone has activity against ovarian cancer resistant to cisplatin and paclitaxel. The drug is well tolerated. Further studies need to be performed when this drug becomes more widely available in the United States.
Assuntos
Carcinoma/tratamento farmacológico , Antagonistas de Hormônios/uso terapêutico , Mifepristona/uso terapêutico , Neoplasias Ovarianas/tratamento farmacológico , Adulto , Antineoplásicos Fitogênicos/farmacologia , Biomarcadores Tumorais/análise , Antígeno Ca-125/análise , Carcinoma/patologia , Cisplatino/farmacologia , Esquema de Medicação , Resistencia a Medicamentos Antineoplásicos , Feminino , Antagonistas de Hormônios/administração & dosagem , Humanos , Mifepristona/administração & dosagem , Neoplasias Ovarianas/patologia , Paclitaxel/farmacologia , Resultado do TratamentoRESUMO
The use of radioactive colloidal phosphorus 32 (32P) in the treatment of epithelial ovarian cancer continues to be controversial. One institution's experience with the use of 32P in 30 patients with epithelial ovarian cancer was reviewed retrospectively. One hundred percent of attempts at placement of 32P intra-abdominally were ultimately successful. The complication rate was 11%. Mean clinical (asymptomatic) disease-free survival in patients with stage III ovarian cancer was as follows: 26 months based on absence of disease at reassessment surgery; 26 months based on microscopic residuum; and 30 months based on minimal (< 5 mm) residuum. Mean disease-free survival in patients with early-stage (stages IC through IIC) ovarian cancer was 66 months.
Assuntos
Braquiterapia , Neoplasias Ovarianas/radioterapia , Radioisótopos de Fósforo/uso terapêutico , Intervalo Livre de Doença , Feminino , Humanos , Estadiamento de Neoplasias , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/patologia , Estudos RetrospectivosAssuntos
Histerectomia/enfermagem , Neoplasias do Colo do Útero/cirurgia , Educação Continuada em Enfermagem , Feminino , Humanos , Histerectomia/métodos , Cuidados Intraoperatórios , Estadiamento de Neoplasias , Cuidados Pós-Operatórios , Cuidados Pré-Operatórios , Neoplasias do Colo do Útero/enfermagem , Neoplasias do Colo do Útero/patologiaRESUMO
Chlamydia trachomatis is becoming increasingly known for its ability to cause severe injury to the female genital tract. Little investigation has been done in its role in diseases of Bartholin's glands. We present what we believe to be the first case report of an abscess of a Bartholin's gland in which Chlamydia trachomatis was a major pathogen. This communication also review the literature concerning the microbiology of Bartholin's gland abscess.
